How Does HRX215 Enhance Liver Regeneration?

The liver possesses remarkable but finite regenerative capacity. Extensive hepatectomy, severe steatosis, chronic inflammation, or fibrosis may prevent the residual liver tissue from recovering its function in time, increasing the risk of post-hepatectomy liver failure. A study published in Cell developed HRX215, a first-in-class MKK4 inhibitor that enhances hepatocyte proliferation by reshaping the MKK4–MKK7/JNK1 signaling network, providing a new pharmacological strategy for promoting liver regeneration.

Keywords: HRX215; MKK4; liver regeneration; MKK7; JNK1; ATF2; ELK1; post-hepatectomy liver failure

1 Biological Basis of Liver Regeneration

1.1 Liver Regeneration Is a Form of Compensatory Growth

The adult liver accounts for approximately 2% of human body weight, and most hepatocytes normally remain mitotically quiescent. Following toxic injury or partial hepatectomy, residual hepatocytes can re-enter the cell cycle and restore an appropriate liver-to-body weight ratio through increases in cell number and changes in cell size. This process mainly represents compensatory growth of the residual liver tissue rather than in situ reconstruction of the resected liver lobes.

1.2 Multiple Cell Types Cooperatively Regulate the Regenerative Response

Hepatocytes are the principal effector cells responsible for regeneration after most acute injuries and partial hepatectomy. Biliary epithelial cells can expand and participate in tissue repair under specific injury conditions. Liver sinusoidal endothelial cells, Kupffer cells, infiltrating immune cells, and hepatic stellate cells regulate hepatocyte proliferation through cytokines, growth factors, extracellular matrix components, and hemodynamic signals.

1.3 Acute and Chronic Injuries Produce Different Regenerative Outcomes

During acute injury, macrophages remove cellular debris and gradually transition toward a pro-repair phenotype, while proliferation of residual hepatocytes and biliary epithelial cells can restore the tissue. Chronic injury causes hepatocyte senescence, persistent inflammation, and hepatic stellate cell activation. Excessive extracellular matrix deposition further restricts cell proliferation and tissue remodeling, shifting the liver from effective repair toward fibrosis.

Table 1. Regenerative Characteristics of the Liver Under Different Conditions

Liver Condition	Hepatocytes and Biliary Cells	Immune and Stromal Responses	Major Outcome
Physiological homeostasis	Low-level self-renewal	Kupffer cells maintain immune surveillance, and hepatic stellate cells remain quiescent	Maintenance of tissue homeostasis
Acute injury	Hepatocytes rapidly enter the cell cycle, accompanied by moderate expansion of biliary cells	Macrophages remove debris and release pro-repair signals	Restoration of tissue structure and function
Chronic injury	Hepatocyte senescence or death and reduced regenerative capacity	Accumulation of pro-inflammatory macrophages and activation of hepatic stellate cells	Persistent inflammation, fibrosis, and functional decline
Extensive hepatectomy	Residual hepatocytes sustain intense proliferative and metabolic demands	Marked changes in portal blood flow and inflammatory signaling	Adequate regeneration or post-hepatectomy liver failure

2 Why Has MKK4 Become a Target for Liver Regeneration?

2.1 MKK4 Is Located Within a Stress-Activated MAPK Network

Mitogen-activated protein kinase kinase 4 (MKK4), also known as MAP2K4, is a dual-specificity protein kinase involved in the regulation of stress-activated protein kinase and MAPK signaling. MKK4 responds to inflammation, oxidative stress, DNA damage, and metabolic stress and regulates JNK and certain p38 MAPK isoforms.

2.2 MKK4 and MKK7 Are Not Functionally Redundant

Both MKK4 and MKK7 participate in JNK activation, but they differ in stimulus responsiveness and substrate preference. MKK7 preferentially activates JNK, whereas MKK4 connects both JNK- and p38-related stress responses. Inhibiting MKK4 does not shut down all JNK signaling but instead alters the signaling balance between the two upstream kinases.

2.3 RNA Interference Screening Identified the Regeneration-Limiting Role of MKK4

In vivo RNA interference screening showed that reducing MKK4 expression in hepatocytes enhances the regenerative capacity of livers subjected to acute or chronic injury. Genetic studies demonstrated that MKK4 silencing shifts the signaling network toward the MKK7–JNK1 axis and activates pro-regenerative transcription factors such as ATF2 and ELK1, suggesting that MKK4 is an important regulatory node that restricts the re-entry of injured hepatocytes into the cell cycle.

3 Discovery and Pharmacological Characteristics of HRX215

3.1 Transition from a Genetically Validated Target to a Small-Molecule Drug

RNA interference can validate the value of MKK4 as a therapeutic target, but tissue delivery, dose control, and clinical application remain challenging. Researchers used the scaffold of a known kinase inhibitor as a chemical starting point and conducted multiple rounds of structural optimization based on kinase activity, cell permeability, selectivity, and pharmacokinetics, ultimately generating the clinical candidate HRX215.

3.2 Kinase Selectivity Is Central to Candidate Selection

MKK4 shares similar ATP-binding regions with other kinases in MAPK pathways. Candidate compounds must therefore avoid directly inhibiting related kinases such as MKK7, JNK1, and BRAF. HRX215 exhibits more than 100-fold selectivity over JNK1, BRAF, and MKK7, allowing relatively specific evaluation of the signaling-remodeling effects produced by MKK4 inhibition.

3.3 HRX215 Exhibits a Developable Exposure Profile

HRX215 combines cell-membrane permeability, oral activity, and pharmacokinetic properties suitable for in vivo studies. Animal experiments and first-in-human studies showed dose-dependent increases in exposure and a half-life compatible with repeated administration, providing a pharmacological basis for perioperative intervention and subsequent clinical evaluation.

4 Mechanisms Through Which HRX215 Enhances Liver Regeneration

4.1 MKK4 Inhibition Attenuates Stress-Mediated Restrictions on Regeneration

Severe liver injury persistently activates stress signaling, causing hepatocytes to undergo cell death, senescence, or proliferative arrest. By inhibiting MKK4 kinase activity, HRX215 attenuates MKK4-related stress restrictions and allows surviving hepatocytes to regain the ability to enter the cell cycle.

4.2 MKK7–JNK1 Forms a Compensatory Pro-Regenerative Signal

MKK7–JNK1 signaling is enhanced following MKK4 inhibition, indicating that HRX215 does not simply suppress the overall activity of stress-activated protein kinase pathways. Instead, it redistributes pathway output. This shift favors the direction of JNK1 activity toward hepatocyte survival, proliferation, and tissue-repair programs.

4.3 ATF2 and ELK1 Initiate Pro-Regenerative Transcriptional Programs

JNK1 activation regulates transcription factors such as ATF2 and ELK1, promoting the expression of genes related to the cell cycle, stress adaptation, and tissue repair. When MKK7 or JNK1 is inhibited, the pro-regenerative effect produced by MKK4 inhibition is markedly attenuated, supporting a central role for the MKK7–JNK1–ATF2/ELK1 axis in the action of HRX215.

4.4 HRX215 Affects Both Proliferation and Cell Death

HRX215 not only increases the number of proliferating hepatocytes positive for Ki67, PCNA, or nucleoside analog incorporation but also reduces hepatocyte apoptosis. The net increase in cell number within regenerating tissue depends on the balance between proliferation and cell death. Cell-cycle entry, cell survival, and recovery of liver function should therefore be evaluated together.

Table 2. Major Signaling Events in HRX215-Promoted Liver Regeneration

Signaling Level	Change Following HRX215 Treatment	Major Evaluation Indicators
Target level	Inhibition of MKK4 kinase activity	MKK4 enzyme activity, target engagement, and kinase selectivity profile
Pathway level	Enhancement of MKK7–JNK1 signaling	MKK7 activity, p-JNK1, and phosphorylation of JNK substrates
Transcriptional level	Enhancement of ATF2- and ELK1-related transcription	p-ATF2, p-ELK1, reporter genes, and transcriptomics
Cellular level	Increased hepatocyte proliferation and reduced apoptosis	Ki67, PCNA, EdU, Caspase-3, and TUNEL
Tissue level	Restoration of liver mass and tissue architecture	Liver-to-body weight ratio, histology, and imaging-based volume measurements
Functional level	Improvement in synthetic, metabolic, and detoxification functions	ALT, AST, bilirubin, albumin, and coagulation function

5 Preclinical and Human Evidence for HRX215

5.1 Mouse Models of Liver Injury and Partial Hepatectomy

In the context of carbon tetrachloride-induced liver injury, HRX215 increases hepatocyte proliferation and reduces apoptosis following partial hepatectomy. These findings support the ability of MKK4 inhibition to enhance the regenerative response of residual hepatocytes in an already injured liver rather than exerting effects exclusively in a healthy liver.

5.2 Models of Steatohepatitis and Chronic Fibrosis

MKK4 inhibition reduces steatosis and fibrosis in models of alcohol-associated steatohepatitis and chronic carbon tetrachloride-induced liver fibrosis. These changes may involve hepatocyte survival, inflammatory responses, metabolic state, and extracellular matrix remodeling and cannot be explained solely by increased hepatocyte proliferation.

5.3 Porcine Models of Extensive Hepatectomy

Porcine livers more closely resemble human livers in volume, architecture, and perioperative physiological changes. Researchers evaluated HRX215 in 80% and 85% hepatectomy models. The results showed that MKK4 inhibition increased hepatocyte proliferation, accelerated recovery of the residual liver tissue, and improved survival following otherwise lethal 85% hepatectomy.

5.4 Potential for Preventing Post-Hepatectomy Liver Failure

Post-hepatectomy liver failure (PHLF) is closely associated with an insufficient future liver remnant, poor residual liver quality, and inadequate regeneration. By increasing the regenerative capacity of residual hepatocytes, HRX215 may expand the safety limits for extensive hepatectomy in selected patients. It cannot replace preoperative assessments of liver volume, liver function, and surgical risk.

5.5 Safety and First-in-Human Studies

Long-term MKK4-silencing studies did not identify a marked increase in the risk of liver tumor development. HRX215 was also well tolerated in repeat-dose toxicity studies in rats and dogs. A first-in-human phase I study showed favorable safety, tolerability, and pharmacokinetic profiles. HRX215 (darizmetinib) has now entered Phase Ib/IIa clinical evaluation in patients undergoing liver resection, with a Phase II study also evaluating enhancement of future liver remnant growth after portal vein embolization.

6 Products Related to HRX215 and Liver Regeneration Research

6.1 Products for Studying the MKK4–MKK7/JNK Pathway

Catalog #	Product Name	Grade & Purity	Mechanism of Action and Research Positioning
V127521	Vemurafenib (PLX4032, RG7204)	Moligand™, ≥98%	A BRAF inhibitor whose chemical scaffold is associated with the lead-discovery process for HRX215; it can be used as a reference for kinase selectivity and structural optimization
S408302	SP600125	Moligand™, 10mM in DMSO	Also known as SP600125, it inhibits JNK1, JNK2, and JNK3 and is used to determine whether the pro-regenerative effects of MKK4 inhibition depend on JNK signaling
S125267	SP600125	Moligand™, ≥98%	Powder-form SP600125 suitable for concentration-gradient studies, combination interventions, and formulation research for animal experiments
J408376	JNK-IN-8	Moligand™, 10mM in DMSO	Covalently inhibits JNK1, JNK2, and JNK3 and can be combined with SP600125 to establish an orthogonal pathway-validation system
M1470376	MAP2K4 Human Pre-designed siRNA Set A		Reduces MAP2K4 expression in human cells and is used to compare the effects of genetic MKK4 silencing with those of pharmacological inhibition by HRX215
M1490814	Map2k4 Mouse Pre-designed siRNA Set A		Used for Map2k4 gene silencing and target-dependency studies in mouse cells or animal-derived samples
M1463874	MAP2K7 Human Pre-designed siRNA Set A		Reduces MAP2K7 expression and is used to verify whether MKK7 mediates compensatory JNK1 activation following MKK4 inhibition
Ab114888	MEK4/MKK4 Antibody	Carrier Free, ExactAb™, Validated, 1.0 mg/mL	Detects MKK4 protein expression and is used to evaluate gene silencing, tissue expression, and changes in protein abundance
Ab111513	Recombinant JNK1/JNK2/JNK3 Antibody	Recombinant, ExactAb™, Validated, See COA	Detects JNK family proteins and is used to analyze MKK4–MKK7 signaling remodeling and changes in JNK expression
Ab111533	Recombinant JNK2 Antibody	Recombinant, ExactAb™, Validated, 0.3 mg/mL	Specifically detects JNK2 and helps distinguish the respective roles of JNK1 and JNK2 in hepatocyte stress responses and regeneration
rp183743	Recombinant Human JNK1 Protein	Carrier Free, Bioactive, ActiBioPure™, His Tag, ≥85%(SDS-PAGE), See COA	Used to evaluate JNK1 enzyme activity, protein interactions, and inhibitor selectivity
Ab089931	Recombinant ATF2 Antibody	Recombinant, ExactAb™, Validated, 0.6 mg/mL	Detects ATF2 protein and is used to evaluate pro-regenerative transcriptional signaling downstream of JNK1
Ab101502	Recombinant ELK1 Antibody	Recombinant, ExactAb™, Validated, 0.5 mg/mL	Detects ELK1 expression and is used to analyze transcriptional responses downstream of MKK7–JNK1 signaling

6.2 Products for Evaluating Hepatocyte Proliferation and Energy Status

Catalog #	Product Name	Grade & Purity	Mechanism of Action and Research Positioning
Ab112015	Recombinant Ki67 Antibody	Recombinant, ExactAb™, Validated, See COA	Detects hepatocytes in active phases of the cell cycle and is used to evaluate hepatocyte proliferation following HRX215 treatment
Ab112020	Ki67 Mouse mAb	Carrier Free, ExactAb™, Azide Free, Validated, See COA	Detects Ki67-positive cells and provides a primary-antibody option from a different host species
Ab176325	PCNA Mouse mAb (TRITC)	ExactAb™, Validated, 0.5 mg/mL	Detects the DNA replication-associated protein PCNA and is suitable for fluorescence imaging of hepatocyte proliferation
E1456506	EdU Cell Proliferation Detection Kit (6-FAM)	BioReagent, Biological Stain, for Fluorescence analysis, for microscopy	Labels newly synthesized DNA through EdU incorporation and quantifies hepatocytes entering S phase
C266180	Cell Counting Kit-8	BioReagent, for detection	Reflects viable cell numbers through cellular metabolic activity and is used to screen the effective concentration and cytotoxicity range of HRX215
E1501756	Enhanced ATP Assay Kit	BioReagent	Quantifies cellular ATP levels and assists in evaluating the energy status and metabolic function of regenerating hepatocytes

6.3 Products for Evaluating Hepatocyte Apoptosis, Cellular Injury, and Functional Status

Catalog #	Product Name	Grade & Purity	Mechanism of Action and Research Positioning
Ab156544	Caspase 3 Mouse mAb	Carrier Free, ExactAb™, Azide Free, Validated, High Performance, PBS Only, ≥95%(SDS-PAGE), 1.0 mg/mL	Detects Caspase-3 protein and is used to evaluate changes in hepatocyte apoptotic pathways
C1373312	Caspase 3 Activity Assay Kit	BioReagent, Suitable for Analysis, Colorimetry	Quantifies Caspase-3 enzyme activity and is used to determine whether HRX215 reduces executioner apoptosis in hepatocytes
C1372489	Caspase 3/7 Activity Assay Kit	BioReagent	Simultaneously measures Caspase-3 and Caspase-7 activities for quantitative analysis of apoptosis in cell or tissue samples
O1456512	One-step TUNEL Apoptosis Assay Kit (Red, Cy3)	BioReagent, for Fluorescence analysis, Biotechnology Grade	Labels DNA breaks with Cy3 fluorescence and is used to localize apoptotic events in tissue sections or cells
A598361	Aladdin ® 555 TUNEL apoptosis Kit (orange red fluorescence)		Detects DNA breaks using orange-red fluorescence and is suitable for multiplex staining with proliferation, nuclear, or tissue markers
T1456509	Colorimetric TUNEL Apoptosis Assay Kit	BioReagent, for microscopy, Colorimetry	Detects DNA breaks through a colorimetric reaction and is suitable for bright-field observation and pathological analysis of apoptosis in liver tissue
L1373310	LDH Cytotoxicity Assay Kit with WST-8	BioReagent, Ready-to-use, for IP	Measures lactate dehydrogenase in culture supernatants to quantify hepatocyte plasma-membrane damage and cytotoxicity
T131055	TMRE [Tetramethylrhodamine, ethyl ester, perchlorate]	for Fluorescence analysis, ≥90%(HPCE)	Detects mitochondrial membrane potential and is used to evaluate mitochondrial function and hepatocyte viability following HRX215 treatment
F746068	Fluo-4 AM	BioReagent, ≥90%(HPLC), 2mM	Detects changes in cytosolic Ca²⁺ and assists in analyzing early signaling responses following hepatectomy or growth-factor stimulation

6.4 Products for Evaluating Liver Injury, Liver Function, and Fibrosis

Catalog #	Product Name	Grade & Purity	Mechanism of Action and Research Positioning
C639782	Carbon tetrachloride standard solution	Analytical Standard, ≥99.9%	Used for carbon tetrachloride quantification, calibration curves, and methodological controls rather than for direct administration in animal models of liver injury
A1527165	Alanine Aminotransferase (ALT) Activity Assay Kit (DNPH, Colorimetric Method)	BioReagent	Detects ALT activity and is used to evaluate the extent of hepatocyte injury and functional recovery following hepatectomy
A1515821	Alanine Aminotransferase (ALT/GPT) Activity Assay Kit (DNPH, Micro Method)	BioReagent	Suitable for detecting ALT activity in small-volume serum samples, cell lysates, or tissue homogenates
A1522030	Aspartate Aminotransferase Activity Assay Kit (Reitman-Frankel, Colorimetric Method)	BioReagent	Detects AST activity and assists in evaluating liver-tissue injury and changes in cellular integrity during regeneration
H1515817	Hydroxyproline (HYP) Content Assay Kit (Ehrlich, Micro Method)	BioReagent	Quantifies hydroxyproline in small-volume liver-tissue samples to evaluate collagen deposition and the extent of liver fibrosis
H1527317	Hydroxyproline Content Assay Kit (Ehrlich's Reagent, Colorimetric Method)	BioReagent	Quantifies hydroxyproline in liver tissue and is used to analyze the effects of HRX215 on chronic liver fibrosis

HRX215 enhances hepatocyte proliferation and survival by inhibiting MKK4 and strengthening the pro-regenerative MKK7–JNK1–ATF2/ELK1 signaling pathway, thereby reducing the risk of liver failure in extensive hepatectomy models. Its principal clinical potential lies in perioperative liver regeneration and small-for-size liver grafts, although its long-term safety, effects in the presence of tumors, and applicability across different underlying liver diseases require further validation.

For more related articles, please see below:

[1] 3D Bioprinting-Driven Regenerative Medicine: Principles, Key Technologies, and Application Prospects

References

[1] Campana L, et al. Liver regeneration and inflammation: from fundamental science to clinical applications. Nat Rev Mol Cell Biol. 2021 Sep;22(9):608-624.

[2] Zwirner et al., First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure, Cell (2024),https://doi.org/10.1016/j.cell.2024.02.023

[3] Wuestefeld T, et al. A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. Cell. 2013 Apr 11;153(2):389-401.